Mallinckrodt Provides a Regulatory Update on Terlipressin

DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Mallinckrodt plc , a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter ... | February 22, 2022

Related Keywords

United States ,Dublin ,Ireland ,Americans ,Steven Romano ,Ryan Taylor ,Danielj Speciale ,Prnewswire Mallinckrodt ,Gastroenterol Hepatol ,Heather Guzzi ,Prashant Pandya ,Company New Drug Application ,Mallinckrodt Pharmaceuticals ,National Organization For Rare Disorders ,Renal Drugs Advisory Committee ,Drug Administration ,United States Census Bureau ,Exchange Commission ,Mallinckrodt Hospital Products Inc ,Green Room Communications ,Mallinckrodt Pharmaceuticals Terlipressin Advisory Committee Briefing Document ,Complete Response Letter ,New Drug Application ,Executive Vice President ,Chief Scientific Officer ,Specialty Brands ,Specialty Generics ,Investor Relations ,Annual Report ,Vice President ,Accessed February ,Accessj Clin ,Nationwide Inpatient Sample ,States Census Bureau ,Hospital Products ,Renal Drugs Advisory ,Mallinckrodt Plc Stock Exchange ,News ,Information ,Press Release ,022 ,Mallinckrodt ,Lobal ,Iopharmaceutical ,Oday ,Nnounced ,Hat ,The ,Wood ,End ,Drug ,Administration ,Gas ,Ssued ,Omplete ,Response ,Etter Mnkkq Ie00bbgt3753 ,